Suven Pharmaceuticals Limited (SUVENPHAR) - Total Liabilities
Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has total liabilities worth Rs11.91 Billion INR (≈ $128.81 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Suven Pharmaceuticals Limited - Total Liabilities Trend (2019–2025)
This chart illustrates how Suven Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. See Suven Pharmaceuticals Limited working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Suven Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Suven Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Uxi Unicomp Technology Co. Ltd. A
SHG:688531
|
China | CN¥516.58 Million |
|
Cousins Properties Incorporated
NYSE:CUZ
|
USA | $4.55 Billion |
|
KONINKLIJKE VOP.UNSP.ADR
F:VPK
|
Germany | €3.54 Billion |
|
Dexus
AU:DXS
|
Australia | AU$5.26 Billion |
|
Hubei Energy Group Co Ltd
SHE:000883
|
China | CN¥53.99 Billion |
|
Novanta Inc
F:1GSN
|
Germany | €704.34 Million |
|
Clear Secure Inc
NYSE:YOU
|
USA | $959.75 Million |
|
Lemonade Inc
NYSE:LMND
|
USA | $1.40 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Suven Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Suven Pharmaceuticals Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Suven Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Suven Pharmaceuticals Limited (2019–2025)
The table below shows the annual total liabilities of Suven Pharmaceuticals Limited from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs11.91 Billion ≈ $128.81 Million |
+485.53% |
| 2024-03-31 | Rs2.03 Billion ≈ $22.00 Million |
-11.77% |
| 2023-03-31 | Rs2.31 Billion ≈ $24.93 Million |
-23.76% |
| 2022-03-31 | Rs3.02 Billion ≈ $32.70 Million |
+2.98% |
| 2021-03-31 | Rs2.94 Billion ≈ $31.76 Million |
-10.48% |
| 2020-03-31 | Rs3.28 Billion ≈ $35.48 Million |
+70.21% |
| 2019-03-31 | Rs1.93 Billion ≈ $20.84 Million |
-- |
About Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more